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Streptokinase for the Treatment of Acute Myocardial Infarction:
A Brief Review of Randomized Trials
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Seattle, Washington
This is a review of the important randomized trials of
intracoronary and intravenous streptokinase therapy for
treatment of acute myocardial infarction. Trials carried
out before 1980failed to recognize the relations between
early coronary reperfusion and myocardial salvage and
therefore have not been included in this review. Seven
studies on intracoronary streptokinase have been re-
viewed. The two largest of these studies, the Western
Washington trial and the Netherlands trial, show a sim-
ilar reduction in early mortality. Two other small studies
demonstrated a trend toward a reduction in mortality
with streptokinase therapy and the other three did not.
One small and two large intravenous streptokinase trials
are reviewed. Of these, the large GISSI trial in Italy
demonstrated a 23% reduction in mortality in patients
Acute myocardial infarction remains one of the major causes
of death in the western world. Each year, approximately
1.5 million Americans will have a myocardial infarction
and, of these, 550,000 will die. A substantial number of
these patients will die before hospitalization, and many within
the first week after the initiation of hospital care. Although
the development of coronary care units has reduced the
mortality of this disease, routine therapy in coronary care
units currently results in an average hospital mortality rate
of 10 to 12%.
Before 1979 there were numerous studies (1-8) that eval-
uated the usefulness of intravenous streptokinase therapy in
acute myocardial infarction. Although some of these showed
a modest positive effect, treatment in all began many hours
after the onset of infarction because the relation between
early coronary artery reperfusion and potential salvage of
ischemic myocardium was not yet appreciated. Once DeWood
et al. (9) demonstrated the presence of an intracoronary
occlusive thrombus in most patients with acute myocardial
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treated within 3 hours from the onset of symptoms and
the Intracoronary Streptokinase in Acute Myocardial
Infarction (ISAM) trial showed a similar trend toward
reduced mortality. The small Western Washington trial
showed an even greater trend toward reduced mortality
but this benefit was limited to patients with anterior
myocardial infarction who received early therapy.
It is concluded that intracoronary and intravenous
streptokinase therapy, when initiated within the first 6
hours of acute myocardial infarction, reduces mortality.
The therapy is most beneficial for those patients with
anterior myocardial infarction and those whocan receive
therapy within the first 2 to 3 hours from the onset of
symptoms.
(J Am Coil CardioI1987;5:28B-32B)
infarction, the potential for thrombolytic therapy became
even more apparent. The relation between early reperfusion
and myocardial salvage had already been recognized in an-
imals (10,11) so that, after the demonstration of the lysis
of thrombi with intracoronary infusion of streptokinase by
Rentrop er al. (12), the scientific basis for early intracoro-
nary streptokinase therapy of acute myocardial infarction
was established. With the confluence of these three impor-
tant facts, this therapy moved forward more rapidly than
any new treatment in the history of cardiology.
This review is limited to discussion of the results of
randomized trials of intracoronary and intravenous strep-
tokinase therapy of acute myocardial infarction. Only trials
carried out since 1980, when our current understanding of
the pathophysiology of acute myocardial infarction had been
established, are included. Although there have been nu-
merous important contributions to this field from nonran-
domized clinical investigations, the effect of thrombolytic
therapy on survival cannot be adequately assessed without
the use of randomized trials because of the well recognized
inherent difficulties in using nonrandomized concurrent or
historical populations of patients to compare the results of
treatment. In most instances, coronary artery angioplasty or
early coronary artery bypass surgery was not a part of the
therapy.
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Figure 1. Twelve month survival for the patients who received
intracoronary (I.e.) streptokinase (open circles) and the control
patients (closed circles). At 30 and 180 days, the survival was
significantly higher in the treatment patients, but by I year the
survival was not significantly improved in the treatment patients.
p -e-- 0.01, (Reproduced with permission from Kennedy JW, et al.
[221·)
Intracoronary Streptokinase
The first major contributions to this field came from Eu-
ropean investigators including Chazov et al. (13) in Russia
and Rentrop et al. (12) in West Germany, who reported on
administration of intracoronary streptokinase for the treat-
ment of acute myocardial infarction.
Initial American trials. The report by Rentrop et al.
generated a great deal of enthusiasm among cardiologists
and resulted in the rapid application of these techniques in
some clinical centers (14-16) and the development of ran-
domized studies in others, Results of two early randomized
trials were published together in June 1983. Khaja et al.
(16) randomized 20 patients to treatment with intracoronary
streptokinase and 20 to control for an average of:).4 hours
after the onset of symptoms of myocardial infarction. The
streptokinase group demonstrated no improvement in car-
diac function after treatment. Anderson et al. (17) random-
ized 50 patients to treatment with intracoronary streptoki-
nase or to routine therapy without early angiography. These
patients were treated earlier-an average of 2,7 hours after
the onset of symptoms-than were the patients of Khaja et
al. and those receiving streptokinase had a significant im-
provement in ejection fraction as compared with the control
patients. In both of these studies, there were fewer deaths
in the streptokinase treated patients.
Raizner et al. (18) randomized 64 patients to intracoro-
nary streptokinase or routine therapy an average of 5,6 hours
after the onset of symptoms. The patients receiving strep-
tokinase demonstrated no improvement in ejection fraction
over that of the control groups; there were fewer deaths in
the control patients, Leiboff et al. (19) also randomized 40
patients with acute myocardial infarction to intracoronary
streptokinase or to a control group, In their series the patients
underwent angiography an average of 4.0 hours after treat-
ment and had an average time to reperfusion of 4.8 hours,
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Figure 2. Survival curves for the patients rand~mize? to throm-
bolytic therapy and theconventionally treated patients In the Neth-
erlands trial. AI the end of a 12 month follow-up, there was
significantly improved survival in the treatment patients, as COIl1-
pared with those who received conventional therapy. (Reproduced
with permission from Simoons ML. ct al. [231,)
There was no difference in ejection fraction between the
two groups and there were fewer deaths in the control pa-
tients. In each of these four small randomized trials. the
number of patients was not large enough to examine the
effect of thrombolytic therapy on mortality, In two of the
trials there were fewer deaths in the control group and in
two there were fewer deaths in the treatment group, It is
important that the only study to show improvement in left
ventricular ejection fraction with streptokinase therapy was
the trial of Andersonet al. (17) in which the patients received
very early therapy,
Rentrop trial. A somewhat larger study was performed
by Rcntrop et al. (20). They randomized 124 patients to a
complex protocol comprising four study groups including
intracoronary streptokinase with and without intracuronary
nitroglycerin. intracoronary nitroglycerin alone and a con-
trol group that did not undergo cardiac catheterization. The
streptokinase infusions were started an average of 5.9 hours
after the onset of symptoms. Only patients with initially
open coronary arteries showed improvement in cardiac func-
tion, There were fewer 30 day deaths in the patients who
did not receive streptokinase,
The Western Washington trial (Fig. J). The largest of
these earlv randomized trials in the United States was the
multicent~r Western Washington study (21,22) comprising
250 patients, 134 randomized to intracoronary streptokinase
and 1If)to the control group. All patients underwent cardiac
catheterization and only those who were shown to have an
occluded or partially thrombosed infarct vessel were ran-
dornizcd. These patients began intracoronary streptokinase
an average of 4.6 hours after the onset of chest pain. The
30 day mortality was significantly lower in the treatment
group (5 of 134 [3,7%1 versus 13 of 116 [11.2'?1c], P <
0.02), At 1 year the mortality was 44% lower in the treat-
ment group but the difference was no longer statistically
significant (p = 0,10),
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tality for patients receiving thrombolytic therapy. A major
difference in these two studies is the average time to treat-
ment. In the Netherlands study, the mean time to treatment
was 3.3 hours and in the Western Washington study it was
4.6 hours. This importantdifference in time to thrombolytic
therapy was associated with a higher angiographic ejection
fraction, at hospital discharge. of 53% in the treated patients
as compared with47% in control patients in the Netherlands
trial. The patients in the Netherlandsstudy who were treated
within 3 hours had an even higher ejection fraction at the
time of discharge angiography (57% in the treated group
versus 47% in the control group, p < 0.0001). By com-
parison, the patients in the Western Washington study who
were studied 8 weeks after entry into the study had no
difference in their radionuclideejection fraction (45.9% for
the treatment group and 46.1% for control subjects). These
observations indicate that early thrombolytic therapy is re-
quired to achieve preservation of ischemic myocardium.
Conclusions from the results of the seven randomized
trials of intracoronary streptokinase. Figure 3 presents
the relative risk of 30 day mortality for these seven trials
(16-22). In aggregate, these trials contain a total of 1,101
patients. The trials that demonstrated lower mortality or a
trend toward lower mortality with intracoronary streptoki-
nase therapy contained 873 patients; those in which strep-
tokinase therapy tended to have negative results contained
228 patients. When these trials are combined for statistical
purposes, there is a significant reduction in mortality with
thrombolytic therapy (p = 0.04).
Although one must be wary of combining data from
randomized trials because each has a different protocol,
different patient characteristics and often different methods
of data analysis, many if not most small randomized trials
are not large enough to have adequate statistical power to
answer important questions such as the effect of treatment
on early or late mortality. Studies such as the GISSI or the
Intravenous Streptokinase in Acute Myocardial Infarction
(ISAM)trial (24-26), despite their large numbersof patients
may not reflect current practice and therefore may have
limited application relative to patient management, in this
or other countries. Despite these potential problems, I be-
lieve that the data derived from these seven trials indicate
that early and I year mortality is significantly reduced by
the early use of intracoronary streptokinase therapy. Al-
though the time limits for the effective use of intracoronary
therapy must vary from patient to patient, depending on
their baseline hemodynamic state, the presence of collateral
flow to the distal bed of the infarct-related artery and the
duration of total occlusion of this artery, it appears that, for
the majority of patients, reperfusion therapy is usually ef-
fective if started in <3 hours and is usually ineffective after
6 hours. Among patients who are seen between 3 and 6
hours, those who haveongoingevidence of myocardial isch-
emia, as demonstrated by continuing chest pain or persistent
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Figure 3. The 95% confidence limits for I month mortality for
seven intracoronary streptokinase randomized trials (from top to
bottom, references 12;18;19;16;17;21;22;23). Those confidence
limits that overlap 0 are notstatistically significant. The two largest
trials both reached statistical significance and demonstrated a re-
duction in I month mortality in the patients randomized to intra-
coronary streptokinase therapy. Figures in parentheses indicate
number of patients.
The Netherlands interuniversity study (Fig. 2). The
interuniversity study from the Netherlands (23) was the sec-
ond randomized study to demonstrate a reduction in early
mortality and the first to have significantly improved long-
term survival. This study included 533 patients who were
randomized by the Zelen technique to conventional cardiac
care without early cardiac catheterizationor to early cardiac
catheterization and immediate intracoronary streptokinase.
The study was planned to allow for changes in the treatment
protocol as improved methods of reperfusion therapy evolved.
In accordance with this plan, after the randomizationof 152
patients to the treatment arm, the protocol was altered to
include initial intravenous streptokinase therapy followed
by additional intracoronary streptokinase or coronary bal-
loon angioplasty, or both, if the patients' coronary anatomy
was suitable for this approach. This trial resulted in a sig-
nificant reduction inearly mortality for the treatmentpatients
as compared with the control group (6.1 versus 11.7%,
p = 0.03) which is an overall reduction in early mortality
of 47%. The I year survival rate was also improved (9.0
versus 16.0%, p = 0.01) as shown by the survival curve
in Figure 2. This 44% reduction in I year mortality is the
same as the trend for reduced mortality in the Western
Washington trial (8.2 versus 14.6%, p = 0.10) although
in this smaller trial this difference did not reach statistical
significance (21).
The Netherlands versus Western Washington trials.
Thus, these two randomizedstudies withsimilar initial treat-
ment protocols but very different overall design resulted in
almost identical percent reductions in early and I year mor-
rxcc Vol. 10. t\o. 5
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ST segment elevation on the electrocardiogram, or both,
are most likely to benefit from treatment with thrombolytic
agents.
The Netherlands trial demonstrated both a reduction in
I year mortality and improvement in left ventricular function
after thrombolytic therapy. On the other hand, the Western
Washington trial resulted in a similar degree of improved
survival but this was not associated with either a reduction
in infarct size or an improvement in ejection fraction in the
treatment patients. This dissociation between survival and
left ventricular function suggests that modest preservation
of ischemic myocardiummay not be evident by radionuclide
ejection fraction measurements carried out with the patient
at rest. This is consistent with the recent studies of Satler
et al. (27), who found that ejection fraction improved in
patients who had a patent infarct vessel after thrombolytic
therapy during isoproterenol infusion but did not improve
in patients who had an occluded infarct vessel. Thus, rel-
atively late reperfusion may preserve a thin layer of subep-
icardial myocardiumthat can provide contractile reserve that
may be demonstrated under conditions of increased levels
of circulating catecholamines. This preserved myocardium
may, at least in part, account for the improved survival of
patients who receive late reperfusion therapy.
Intravenous Streptokinase
Since 1980 there have been two large randomized mul-
ticenter trials of intravenous streptokinase therapy for acute
myocardial infarction from Europe and onc smaller trial
from the United States as well as several other smaller
studies that were too limited to evaluate the effect of treat-
ment on survival. The most important of these studies is
the GISSI trial (24) which was carried out on nearly 12,000
patients in a large number of coronary care units in Italy.
Because of the importance or this study, it is described
separately in this supplement (21'\) and will he discussed here
only to compare the results with other studies.
The intravenous streptokinase in acute myocardial
infarction trial (ISAM). The ISAM multicenter trial was
carried out in clinical centers in West Germany, Switzerland
and Canada (25,26). The goal of the study was to determine
the effect of intravenous streptokinase given as a I hour
infusion of 1.5 million IU on 21 day survival of patients
with acute myocardial infarction. The study enrolled 1,741
patients and the mortality at2l days was 6.3170 in the treat-
ment group and 7. I% in the control group (difference not
significant). In patients treated under 3 hours, the difference
was 5.2 versus 6.5%, or a 20% reduction in mortality, but
this difference was also not significant although similar to
the 23% reduction in mortality for this subset of patients in
the GISSI trial. These results are difficult to apply to the
management of most patients with acute myocardial infarc-
tion because the mortality was extremely low in both the
treatment and control groups. For example. the mortality in
the control group in the GISSI study was 12% in patients
treated in <3 hours and 14 to 15% in those treated between
3 and 6 hours, as compared with 7. I% of those treated
between 3 and 6 hours in the ISAM trial. The 21 day mor-
tality rate in the Western Washington intracoronary trial (2I)
was 11.2% in the control group and in the companion West-
ern Washington intravenous trial (29) the control group mor-
tality rate was 9.7%. In the Netherlands trial (23), the con-
trol group mortality rate at 30 days was 11.7% or nearly
identical to that in the Western Washington trial, but 39%
higher than that in the ISAM study.
With this difference in the baseline risk of the patients
in the ISAM study, I believe that the results can be applied
only to very low risk patients with acute myocardial in-
farction. These results suggest that early therapy can reduce
mortality in low risk patients by about 20%, which may
justify the use of these agents in some patients. Unfortu-
nately, the long-term outlook of the patients in the ISAM
study (26) was not so satisfactory. At a mean follow-up of
7 months the mortality rate was 10.9% for the treatment
group and 11.1 % for the control group. This was due to a
higher mortality in the patients with anterior infarction in
the treatment as compared with the control group (20. I
versus 18.4%). In contrast to findings in all other studies
currently available, among treated patients, those with in-
ferior infarction had a more favorable outcome than did
those with anterior infarction. At the 7 month follow-up,
the treatment patients with inferior infarctionhad a mortality
rate of 10.2% and the control patients a mortality rate of
14.1%, although thesedifferences were not significant. These
investigators concluded that the treatment patients with an-
terior myocardial infarction had a higher mortality because
of a high rate of reinfarction and that additional procedures
such as coronary artery angioplasty or revascularization sur-
gery may be necessary to improve the survival of these
patients.
The Western Washington intravenous streptokinase
in myocardial infarction trial. This trial (29) entered 368
patients over a period of 3 years with 191 randomized to
streptokinase. 1.5 million IU infused over I hour, and 177
control patients who were managed in coronary care units
with routine care. The primary end point of the trial was
14day mortality with secondary end points of infarct vessel
patency. residual left ventricular function and infarct size
determined with radionuclide techniques at 8 weeks after
infarction, and 6 month and long term survival. The )4 day
mortality was 9.7% in the control group and 6.3% in the
patients receiving streptokinase (p = 0.23). There were 67
patients with anterior infarction in both groups and the mor-
tality was 1(1.5% in the treatment and 22.5% in the control
group (p ~ O.06). In contrast to this strong trend for reduced
mortality in the treated patients with anterior infarction, the
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patients with inferior infarction had increased mortality in
the treatment group (4.0 versus 1.8%. p = 0.32).
The survival up to 3 years for the total group of patients
was similar in the treatment and control groups. However.
the patients with anterior myocardial infarctionhad a mark-
edly improved survival. At 1 year. the survival was 83%
for the treatment patients and 70% for the controls. and for
the entire period of follow-up the difference in survival was
significant (p = 0.05). Thus, there was a 43% reduction in
I year mortality for the treatment groups with anterior in-
farction and no reduction in mortality for the patients with
inferior infarction. This finding is consistent with those of
the first Western Washington intracoronary streptokinase
trial in which most of the overall early and 1 year reduction
in mortality was due to reduced mortality in the patients
with anterior infarction.
Summary
The results of these seven intracoronary and three intra-
venous streptokinase randomized trials described in this re-
view provideconvincing evidence that this therapy improves
survival in some patients with acute myocardial infarction.
To be most effective. therapy must be initiated as early as
possible and is usually ineffective if not started within 6
hours of the onset of symptoms. If therapy is started within
3 hours of symptom onset, improved global left ventricular
function usually occurs. Data from these trials are somewhat
contlicting but the major beneficial effect of this therapy
appears to occur in patients with anterior myocardial in-
farction, with little or no benefit for those with inferior
infarction.
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